Hepatitis B vaccine recombinant - MedImmune
Latest Information Update: 08 Dec 1998
At a glance
- Originator MedImmune
- Developer MedImmune; sanofi pasteur
- Class Hepatitis B vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 26 May 1995 Discontinued-Preclinical for Hepatitis B in USA (IM)